Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
58
AZN Quote, Financials, Valuation and Earnings
Last price:
$90.01
Seasonality move
:
0.41%
Day range:
$89.77 - $90.87
52-week range:
$61.24 - $94.02
Dividend yield:
1.74%
P/E ratio:
29.90x
P/S ratio:
4.84x
P/B ratio:
6.08x
Volume:
5.3M
Avg. volume:
5M
1-year change:
34.82%
Market cap:
$279.1B
Revenue:
$54.1B
EPS (TTM):
$3.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$14.8B | $1.13 | 4.92% | 128.14% | $96.86 |
|
AMGN
Amgen, Inc.
|
$9B | $5.01 | 4.56% | 309.55% | $324.25 |
|
AUTL
Autolus Therapeutics Plc
|
$21.3M | -$0.23 | 84624.25% | -288.08% | $9.52 |
|
GSK
GSK Plc
|
$11B | $1.26 | 5.82% | 137.07% | $49.35 |
|
MRNA
Moderna, Inc.
|
$869.9M | -$2.16 | -35.16% | -5.21% | $35.78 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.6B | $9.64 | -1.16% | 33.42% | $781.13 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$90.03 | $96.86 | $279.1B | 29.90x | $0.52 | 1.74% | 4.84x |
|
AMGN
Amgen, Inc.
|
$340.16 | $324.25 | $183.2B | 26.30x | $2.38 | 2.8% | 5.13x |
|
AUTL
Autolus Therapeutics Plc
|
$1.57 | $9.52 | $417.8M | -- | $0.00 | 0% | 8.15x |
|
GSK
GSK Plc
|
$48.57 | $49.35 | $97.6B | 13.85x | $0.42 | 3.45% | 2.38x |
|
MRNA
Moderna, Inc.
|
$25.49 | $35.78 | $10B | -- | $0.00 | 0% | 4.42x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$722.80 | $781.13 | $76B | 17.30x | $0.88 | 0.49% | 5.59x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
41.56% | 0.163 | 13.71% | 0.66x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
GSK
GSK Plc
|
52.36% | -0.071 | 27.67% | 0.53x |
|
MRNA
Moderna, Inc.
|
7.29% | 0.934 | 7.28% | 3.30x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | 0.078 | 4.57% | 3.19x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$11.2B | $3.6B | 12.62% | 22.01% | 23.52% | $3.5B |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
GSK
GSK Plc
|
$8.5B | $3.5B | 19.21% | 42.84% | 30.08% | $1.8B |
|
MRNA
Moderna, Inc.
|
$757M | -$260M | -27.85% | -30.18% | -25.59% | -$880M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen, Inc. has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 33.55%. AstraZeneca PLC's return on equity of 22.01% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of $96.86, signalling upside risk potential of 7.59%. On the other hand Amgen, Inc. has an analysts' consensus of $324.25 which suggests that it could fall by -4.68%. Given that AstraZeneca PLC has higher upside potential than Amgen, Inc., analysts believe AstraZeneca PLC is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 AMGNAmgen, Inc.10 15 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.74%. Amgen, Inc. offers a yield of 2.8% to investors and pays a quarterly dividend of $2.38 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen, Inc.'s is not.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Amgen, Inc. quarterly revenues of $9.6B. AstraZeneca PLC's net income of $2.5B is lower than Amgen, Inc.'s net income of $3.2B. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.90x while Amgen, Inc.'s PE ratio is 26.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.84x versus 5.13x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.84x 29.90x $15.1B $2.5B AMGNAmgen, Inc.5.13x 26.30x $9.6B $3.2B
-
Which has Higher Returns AZN or AUTL?
Autolus Therapeutics Plc has a net margin of 16.69% compared to AstraZeneca PLC's net margin of -373.3%. AstraZeneca PLC's return on equity of 22.01% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About AZN or AUTL?
AstraZeneca PLC has a consensus price target of $96.86, signalling upside risk potential of 7.59%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 506.51%. Given that Autolus Therapeutics Plc has higher upside potential than AstraZeneca PLC, analysts believe Autolus Therapeutics Plc is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is AZN or AUTL More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.
-
Which is a Better Dividend Stock AZN or AUTL?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.74%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or AUTL?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Autolus Therapeutics Plc quarterly revenues of $21.1M. AstraZeneca PLC's net income of $2.5B is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.90x while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.84x versus 8.15x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.84x 29.90x $15.1B $2.5B AUTLAutolus Therapeutics Plc8.15x -- $21.1M -$78.6M
-
Which has Higher Returns AZN or GSK?
GSK Plc has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 25.09%. AstraZeneca PLC's return on equity of 22.01% beat GSK Plc's return on equity of 42.84%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B GSKGSK Plc73.8% $1.32 $45.1B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of $96.86, signalling upside risk potential of 7.59%. On the other hand GSK Plc has an analysts' consensus of $49.35 which suggests that it could grow by 1.6%. Given that AstraZeneca PLC has higher upside potential than GSK Plc, analysts believe AstraZeneca PLC is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 GSKGSK Plc1 5 1 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison GSK Plc has a beta of 0.470, suggesting its less volatile than the S&P 500 by 52.951%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.74%. GSK Plc offers a yield of 3.45% to investors and pays a quarterly dividend of $0.42 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. GSK Plc pays out 94.89% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than GSK Plc quarterly revenues of $11.5B. AstraZeneca PLC's net income of $2.5B is lower than GSK Plc's net income of $2.9B. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.90x while GSK Plc's PE ratio is 13.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.84x versus 2.38x for GSK Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.84x 29.90x $15.1B $2.5B GSKGSK Plc2.38x 13.85x $11.5B $2.9B
-
Which has Higher Returns AZN or MRNA?
Moderna, Inc. has a net margin of 16.69% compared to AstraZeneca PLC's net margin of -19.69%. AstraZeneca PLC's return on equity of 22.01% beat Moderna, Inc.'s return on equity of -30.18%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B MRNAModerna, Inc.74.51% -$0.51 $10.1B -
What do Analysts Say About AZN or MRNA?
AstraZeneca PLC has a consensus price target of $96.86, signalling upside risk potential of 7.59%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 40.36%. Given that Moderna, Inc. has higher upside potential than AstraZeneca PLC, analysts believe Moderna, Inc. is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 MRNAModerna, Inc.4 15 1 -
Is AZN or MRNA More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.
-
Which is a Better Dividend Stock AZN or MRNA?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.74%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MRNA?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Moderna, Inc. quarterly revenues of $1B. AstraZeneca PLC's net income of $2.5B is higher than Moderna, Inc.'s net income of -$200M. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.90x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.84x versus 4.42x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.84x 29.90x $15.1B $2.5B MRNAModerna, Inc.4.42x -- $1B -$200M
-
Which has Higher Returns AZN or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 38.89%. AstraZeneca PLC's return on equity of 22.01% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About AZN or REGN?
AstraZeneca PLC has a consensus price target of $96.86, signalling upside risk potential of 7.59%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 8.07%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than AstraZeneca PLC, analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 REGNRegeneron Pharmaceuticals, Inc.16 8 0 -
Is AZN or REGN More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.
-
Which is a Better Dividend Stock AZN or REGN?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.74%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or REGN?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. AstraZeneca PLC's net income of $2.5B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.90x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.84x versus 5.59x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.84x 29.90x $15.1B $2.5B REGNRegeneron Pharmaceuticals, Inc.5.59x 17.30x $3.8B $1.5B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
